Penumbra Inc

Capital Structure and Liquidity Penumbra maintains a robust liquidity position with a current ratio of 6.64, indicating strong short-term financial health. The company's debt-to-equity ratio is 0.0, reflecting a conservative capital structure with no long-term debt obligations. Cash and equivalents amount to $186.9 million, supported by operating cash flow of $238.7 million and free cash flow of $174.9 million in FY2025. ### Profitability and Returns Penumbra's profitability is strong, with a return on equity (ROE) of 12.45% and a return on assets (ROA) of 9.73%. These metrics outperform the industry median for medical equipment firms, which typically range between 8-10% ROE and 6-8% ROA. The company's gross margin of 66.6% (calculated as $942.4 million gross profit / $1.4 billion revenue) is also above the industry median of 55-60%, indicating efficient cost management and pricing power. ### Segments and Geographic Exposure Penumbra operates in two primary segments: Thrombectomy and Embolization. The Thrombectomy segment accounts for the majority of revenue, with a focus on stroke and pulmonary embolism treatments. The Embolization segment includes products for vascular access and embolization procedures. Geographically, the company is heavily concentrated in the United States, which accounts for over 70% of total revenue. International markets, including Europe, Canada, and Australia, represent the remaining 30%. ### Growth Trajectory Penumbra's revenue grew to $1.4 billion in FY2025, up from $879.1 million in the first nine months of the year. The company's outlook for FY2026 is positive, with expected revenue growth driven by continued adoption of its thrombectomy technologies and expansion into new international markets. The acquisition agreement with Boston Scientific Corporation is expected to further accelerate growth through expanded distribution and R&D capabilities. ### Risk Factors Penumbra faces moderate risk from the pending acquisition by Boston Scientific Corporation, which could be terminated under certain circumstances, leading to transaction-related costs and potential stock price volatility. The company also faces competition from established medical device firms and the risk of product obsolescence. However, the risk assessment indicates no immediate liquidity or dilution flags, with low risk scores for both categories. ### Recent Events In Q3 2025, Penumbra reported net income of $45.9 million, with revenue of $354.7 million. The company also announced the wind down of its immersive healthcare business, which had previously incurred $115.3 million in impairment charges in 2024. No impairment charges were recorded in 2025, indicating successful exit from this non-core segment.